Foam sclerotherapy is a clinical procedure for the treatment of unhealthy veins. The aim of this study was to investigate the effect of sulodexide (SUL) on stability of foams prepared using polidocanol (POL) and sodium tetradecyl sulfate (STS) detergents, more specifically with 0.25% aethoxysclerol and 0.2% Fibro-Vein sclerosing solutions.
Methods
Foams were produced by the Tessari method using three different weight ratios of POL-SUL and STS-SUL (1:0, 1:1, and 1:3).
Results
The half-life of STS foams resulted as follows: 82 ± 1.6 s, 101.8 ± 2.6 s, and 109.7 ± 2.1 s for 1:0, 1:1, and 1:3 STS-SUL weight ratios, respectively. The same ratios were used for POL foams with the following results: 90.6 ± 3 s, 106.8 ± 2.6 s, and 107.6 ± 2.7 s for 1:0, 1:1, and 1:3 POL-SUL weight ratios, respectively.
Conclusion
The addition of SUL in sclerosing solutions can prolong the half-life of foams, and it could be potentially used as a foam stabilizer.
Fiorillo AS, Critello CD, Pullano AS, et al. Acoustic cavitation for producing foam in sclerosant drugs. In: AIET international annual conference 2015, IEEE, Naples, Italy, 14–16 October 2015.
4.
YamakiTNozakiMIwasakaS. Comparative study of duplex-guided foam sclerotherapy and duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency. Dermatol Surg2004; 30: 718–722.
5.
de FranciscisSNobileCGALarosaEet al.Air contamination in the sclerosing foam for the treatment of varicose veins. Phlebology2016; 31: 96–100.
6.
TessariL. Nouvelle technique d'obtention de la sclero-mousse. Phlebologie2000; 53: 129–133.
7.
GeuxJ-JSclerofoam for treatment of varicose veins. In: BerganJJ (ed). The vein book, Cambridge, MA: Elsevier Academic Press, 2014, pp. 159.
8.
Smarandache A, Moreno-Moraga J, Staicu A, et al. Applications of polidocanol in varicose vein treatment assisted by exposure to Nd:YAG laser radiation. In: Dumitras DC (ed.) Nd YAG laser. In Tech, 2012, pp.224–254.
9.
CarugoDAnkrettDNO'ByrneVet al.The role of clinically-relevant parameters on the cohesiveness of sclerosing foam in a biomimetic vein model. J Mater Sci: Mater Med2015; 26: 258.
10.
RaoJGoldmanMP. Stability of foam in sclerotherapy: differences between sodium tetradecyl sulfate and polidocanol and the type of connector used in the double-syringe system technique. Dermatol Surg2005; 31: 19–22.
11.
Van DeurzenBCeulenRPTellingsSSet al.Polidocanol concentration and time affect the properties of foam used for sclerotherapy. Dermatol Surg2011; 37: 1448–1455.
12.
WongKChenTConnorDEet al.Basic physiochemical and rheological properties of detergent sclerosants. Phlebology2015; 30: 339–349.
13.
HoskinsPRLawfordPVDoyleBJ. Cardiovascular biomechanics, Switzerland: Springer International Publishing, 2017, pp. 15–16.
14.
ChenAWLiuYRLiKaiet al.An investigation on the influence of hyaluronic acid on polidocanol foam stability. Dermatol Surg2016; 42: 56–58.
15.
NecasJBartosikovaLBraunerPet al.Hyaluronic acid (hyaluronan): a review. Veterinarni Medicina2008; 53: 397–411.
16.
Kuo JW. Practical aspects of hyaluronan based medical products. Taylor & Francis Group, LLC, Boca Raton: Florida, 2006, p.181.
17.
KwonSGHongJWRohTSet al.Ischemic oculomotor nerve palsy and skin necrosis caused by vascular embolization after hyaluronic acid filler injection: a case report. Ann Plast Surg2013; 71: 333–334.
18.
HirshRJCohenJLCarruthersJD. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg2007; 33: 357–360.
19.
GlaichASCohenJLGoldbergLH. Injection necrosis of the glabella: protocol for prevention and treatment after use of dermal fillers. Dermatol Surg2006; 32: 276–281.
20.
CohenJLBiesmanBSDayanSHet al.Treatment of hyaluronic acid filler–induced impending necrosis with hyaluronidase: consensus recommendations. Aesth Surg J2015; 35: 844–849.
21.
BeleznayKHumphreySCarruthersJDAet al.Vascular compromise from soft tissue augmentation: experience with cases and recommendations for optimal outcomes. J Clin Aesthet Dermatol2014; 7: 37–43.
22.
ZanioloOEandiM. Sulodexide: implicazioni cliniche ed economiche. Farmeconomia e percorsi terapeutici2005; 6: 105–118.
23.
Lasierra-CirujedaJCoronelPAzaMJet al.Use of sulodexide in patients with peripheral vascular disease. J Blood Medic2010; 1: 105–115.
24.
AndreozziGM. Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs2012; 12: 73–81.
25.
LauverDALucchesiBR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev2006; 24: 214–226.
26.
CerielloAQuatraroAMarchiEet al.Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide. Diabete Metabol1993; 19: 225–229.
27.
RaoJWildmoreJKGoldmanMP. Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatol Surg2005; 31: 631–635.
28.
ParsiK. Interaction of detergent sclerosants with cell membranes. Phlebology2015; 30: 306–315.
YiannakopoulouE. Safety concerns for sclerotherapy of telangiectases, reticular and varicose veins. Pharmacology2016; 98: 62–69.
33.
KulkarniSRMessergerDESlimFJAet al.The incidence and characterization of deep vein thrombosis following ultrasound-guided foam sclerotherapy in 1000 legs with superficial venous reflux. J Vasc Surg: Venous Lymphat Disord2013; 1: 231–238.
34.
MillerTGoudeMCMcDevittTCet al.Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery. Acta Biomater2014; 10: 1705–1719.
35.
ParsiK. Interaction of detergent sclerosants with cell membranes. Phlebology2015; 30: 306–315.
36.
NastasaVSamarasKAmpatzidisTDet al.Properties of polidocanol foam in view of its use in sclerotherapy. Int J Pharm2015; 478: 588–596.
37.
SarvananthanTShepherdACWillenbergTet al.Neurological complications of sclerotherapy for varicose veins. J Vasc Surg2012; 55: 243–251.
38.
Raymond-MartimbeauP. Air embolism complications associated with sclerotherapy. Phlebologie2012; 65: 20–27.
